Applications of Immunosequencing in Infectious Disease Research, Upcoming Webinar Hosted by Xtalks
TORONTO (PRWEB) May 14, 2020 -- In this webinar, Dr. Boland and Dr. Polaske will highlight infectious disease and vaccine research, presenting published studies where immunoSEQ Technology was leveraged. Topics will include repertoire properties associated with disease and vaccine responses, identifying antigen-specific clones, tracking clones over time and how repertoire and clone-level data can be integrated with clinical data to drive understanding and progress in the field.
Additionally, the speakers will describe different ways to work with Adaptive Biotechnologies, including an upgraded human T-Cell Receptor Beta (TCRB) Kit to perform the gold-standard immunosequencing in your own lab, as well as opportunities to help contribute to the TCR-Antigen Map.
Join Katie Boland, DVM, PhD, Senior Manager, Scientific Services and Nathan Polaske, PhD, Scientific Liaison, Research Products in a live webinar on Tuesday, May 26, 2020 at 1pm EDT (10am PDT).
For more information or to register for this event, visit Applications of Immunosequencing in Infectious Disease Research.
immunoSEQ is For Research Use Only. Not for use in diagnostic procedures.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks, visit http://xtalks.com.
For information about hosting a webinar, visit http://xtalks.com/why-host-a-webinar/.
Sydney Perelmutter, Xtalks, +1 (416) 977-6555 x 352, [email protected]
Share this article